The FDA is seeking comments on black box warning for women's hormone therapy
The FDA is currently seeking public comments regarding the black box warning on women’s hormone therapy products for menopause. Here’s what you need to know:
Background: Since the early 2000s, all estrogen-containing menopause hormone therapies in the U.S. have carried a black box warning about increased risks of breast cancer, cardiovascular events, stroke, and dementia—based on findings from the Women’s Health Initiative (WHI). However, a growing body of experts, including original WHI researchers, now argue these risks were overstated, particularly for younger women and those using low-dose or non-oral formulations. They assert the warning discourages many who could benefit, especially from local (vaginal) estrogen therapy, which is not thought to increase these systemic risks in the same way[1][2][3][4][5].
Recent Action: On July 17, 2025, the FDA convened a panel of menopause and women’s health experts to review whether these warnings are still appropriate. The panel discussed updated data highlighting differences in risk based on age, therapy type, formulation, and timing of initiation. Panelists generally favored revising or removing the black box warning, especially for low-dose, vaginal estrogen used for localized symptoms.
Public Comment Period: Following the meeting, the FDA formally opened a public comment period inviting submissions from clinicians, researchers, patients, and the general public. The agency is particularly interested in updated evidence on the risks and benefits of hormone therapy—including differences due to age, formulation, timing, and route of administration—and wants to hear about patient experiences and perspectives.
· SHORT SUMMARY PODCAST:
How to Submit a Comment
· Deadline: 11:59 p.m. Eastern Time (ET), September 24, 2025.
· Where: Submit comments through Regulations.gov under docket number FDA-2025-N-2589. Click here: Comment Now
· What to Include: You may provide evidence, opinions, or experiences regarding the risks and benefits of menopause hormone therapy (especially as relates to cancer, cardiovascular disease, bone health, cognition, or genitourinary symptoms), and whether the black box warning is justified for all types of treatments.
For professionals submitting evidence, references to published studies or experiences with different formulations/routes (oral/systemic vs. vaginal/local) are encouraged. The FDA will consider all comments received by the deadline in deciding whether to revise the warning label but will not respond individually.
This is a significant opportunity for those in the clinical and research community—as well as patients and advocates—to influence FDA labeling and access to hormone therapies for menopause.
References:
_________________________________________________
The problem is that later studies showed these risks depend on age, timing, dose, and route of use. For women under 60 or within 10 years of menopause, benefits often outweigh risks. Low-dose vaginal estrogen has little to no systemic effect.
The FDA is currently seeking public comments regarding the black box warning on women’s hormone therapy products for menopause. Here’s what you need to know:
Background: Since the early 2000s, all estrogen-containing menopause hormone therapies in the U.S. have carried a black box warning about increased risks of breast cancer, cardiovascular events, stroke, and dementia—based on findings from the Women’s Health Initiative (WHI). However, a growing body of experts, including original WHI researchers, now argue these risks were overstated, particularly for younger women and those using low-dose or non-oral formulations. They assert the warning discourages many who could benefit, especially from local (vaginal) estrogen therapy, which is not thought to increase these systemic risks in the same way[1][2][3][4][5].
Recent Action: On July 17, 2025, the FDA convened a panel of menopause and women’s health experts to review whether these warnings are still appropriate. The panel discussed updated data highlighting differences in risk based on age, therapy type, formulation, and timing of initiation. Panelists generally favored revising or removing the black box warning, especially for low-dose, vaginal estrogen used for localized symptoms.
Public Comment Period: Following the meeting, the FDA formally opened a public comment period inviting submissions from clinicians, researchers, patients, and the general public. The agency is particularly interested in updated evidence on the risks and benefits of hormone therapy—including differences due to age, formulation, timing, and route of administration—and wants to hear about patient experiences and perspectives.
· SHORT SUMMARY PODCAST:
How to Submit a Comment
· Deadline: 11:59 p.m. Eastern Time (ET), September 24, 2025.
· Where: Submit comments through Regulations.gov under docket number FDA-2025-N-2589. Click here: Comment Now
· What to Include: You may provide evidence, opinions, or experiences regarding the risks and benefits of menopause hormone therapy (especially as relates to cancer, cardiovascular disease, bone health, cognition, or genitourinary symptoms), and whether the black box warning is justified for all types of treatments.
For professionals submitting evidence, references to published studies or experiences with different formulations/routes (oral/systemic vs. vaginal/local) are encouraged. The FDA will consider all comments received by the deadline in deciding whether to revise the warning label but will not respond individually.
This is a significant opportunity for those in the clinical and research community—as well as patients and advocates—to influence FDA labeling and access to hormone therapies for menopause.
References:
- Kritz, F. (2025, July 25). Why some experts want the FDA to rethink menopause hormone therapy guidance. NPR. https://www.npr.org/sections/shots-...-5477644/menopause-hormone-therapy-fda-health
- Howard, J. (2025, July 24). Experts call for updated guidance on menopause hormone treatment. CNN. https://www.cnn.com/2025/07/24/health/menopause-hormone-treatment-wellness
- Owens, C. (2025, July 18). FDA under pressure to revisit menopause hormone therapy warnings. Axios. https://www.axios.com/2025/07/18/fda-menopause-hormone-therapy
- Urology Times staff. (2025, July 16). Experts urge FDA to remove black box warning on low-dose vaginal estrogen. Urology Times. https://www.urologytimes.com/view/e...lack-box-warning-on-low-dose-vaginal-estrogen
- Contemporary OB/GYN staff. (2025, July 15). Experts urge FDA to revise boxed warnings on hormone therapies for menopause. Contemporary OB/GYN. https://www.contemporaryobgyn.net/v...d-warnings-on-hormone-therapies-for-menopause
- U.S. Food and Drug Administration. (2025, July 17). FDA expert panel on menopause and hormone replacement therapy in women. FDA. https://www.fda.gov/patients/fda-ex...nd-hormone-replacement-therapy-women-07172025
- NPR. (2025, July 25). Transcript: Menopause hormone therapy and FDA health policy [Radio broadcast transcript]. NPR. https://www.npr.org/transcripts/nx-s1-5477644
- U.S. Food and Drug Administration. (2025, July 21). FDA request for comments: Menopause hormone therapies (Docket No. FDA-2025-N-2589-0001). Regulations.gov. https://www.regulations.gov/document/FDA-2025-N-2589-0001
- U.S. Food and Drug Administration. (2025, July 21). FDA statement on hormone therapies for menopause [Press release]. GovDelivery. https://content.govdelivery.com/accounts/USFDA/bulletins/3eb6f75
_________________________________________________
FDA Black Box Warning on Menopause Hormone Therapy (HRT)
1. Why the Black Box Warning Exists
In 2003, the FDA required a black box warning on all estrogen-containing menopause hormone therapy (HRT) products. This happened after the Women’s Health Initiative (WHI) study reported increased risks of breast cancer, heart disease, stroke, and dementia in women who were given oral estrogen, with or without progestin. The women in this study were on average 63 years old.The problem is that later studies showed these risks depend on age, timing, dose, and route of use. For women under 60 or within 10 years of menopause, benefits often outweigh risks. Low-dose vaginal estrogen has little to no systemic effect.
2. What the Evidence Now Shows
- Breast Cancer (Estrogen Alone): No increase in risk, and possibly lower risk for women under 60.
- Heart Disease: When started early (before age 60 or soon after menopause), HRT reduces the risk of fatal heart attacks by 25–50%.
- Stroke and Blood Clots: Lower risks with transdermal (patch) or low-dose oral forms compared to older oral drugs.
- Vaginal Estrogen: Safe, with no link to breast cancer, stroke, dementia, or blood clots. Blood estrogen levels stay in the post-menopausal range.
3. What Professional Groups Say
- North American Menopause Society (NAMS): The benefits outweigh the risks for most women under 60 with symptoms. They strongly recommend removing the boxed warning for vaginal estrogen.
- ACOG and Other Societies: Support labeling that is specific to age, dose, and route of treatment, and encourage shared decision-making.
4. FDA Expert Panel (July 17, 2025)
The FDA held a public expert panel meeting with 12 leading doctors and researchers. They reviewed new evidence and debated whether the black box warning should stay.Key Takeaways:
- Vaginal Estrogen: Safe for all women. Experts unanimously recommended removing the boxed warning.
- Systemic HRT (under 60): Benefits outweigh risks, especially for heart health and bone protection.
- Labeling: Needs to reflect differences in age, dose, and route instead of a one-size-fits-all warning.
- Impact of the Warning: It creates fear and confusion, leading to undertreatment of menopause symptoms.
5. Criticisms
Some health policy experts worry the panel was biased toward industry and relied too much on observational studies. They want the FDA to keep clear language on potential harms.6. Next Steps
- Public Comments: The FDA opened docket FDA-2025-N-2589 on July 28, 2025. Comments are accepted until September 24, 2025.
- FDA Review: The agency will consider comments, new data, and expert input before making any labeling changes in late 2025 or 2026.
7. What Happens if the Black Box is Removed?
- For Women: More doctors may prescribe low-dose vaginal estrogen and systemic HRT earlier, improving access to treatment.
- Health Outcomes: Could lower rates of painful menopause symptoms, urinary infections, bone fractures, and possibly early heart disease deaths.
- Insurance and Access: Insurers may expand coverage once the highest-level safety warning is gone.
- Research: More studies are needed on transdermal vs oral estrogen, dementia outcomes, and safety for women with a history of breast cancer.
Bottom Line
The 2003 black box warning painted all hormone therapy with the same broad brush. Two decades of research show the risks are lower, especially for younger women and low-dose vaginal estrogen. Many experts, including the FDA’s 2025 panel, support removing or revising the warning to better reflect modern evidence.
Last edited: